Benefit of Carbohydrate Deficient Transferrin to Detect Chronic Alcohol Abuse in the Elderly (NCT02822911) | Clinical Trial Compass
CompletedNot Applicable
Benefit of Carbohydrate Deficient Transferrin to Detect Chronic Alcohol Abuse in the Elderly
France194 participantsStarted 2016-03
Plain-language summary
Alcohol misuse affects 5 million people in France. Even though the elderly are also concerned by this pathology, there is not much information about chronic alcohol misuse of this population in particular.
Biological markers like gamma-glutamyltranspeptidase (GGT), mean corpuscular volume (MCV) and carbohydrate deficient transferrin (CDT) are usually used to detect alcohol abuse. As a biological marker of alcohol misuse, the specificity of the CDT is known to be superior to the GGT as well.
However, when it comes to the elderly, alcoholism diagnosis tools are based on research of younger populations.
This study aims to evaluate the benefit of the CDT to detect chronic alcohol use in the elderly.
Who can participate
Age range
60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* At least 60 years old
* Patients hospitalized for a day or more in the Geriatrics Department of Mulhouse, GHRMSA :
* Coming from home within 48 hours after admission to the GHRMSA
* Study procedures performed within 72 hours after admission to the GHRMSA
* Or new members of the General Practitioner Support Association of Alsace, France (translated in French as the "RAG") living in Mulhouse, Thann and Saint Louis cities (France) :
* Living at home and joining the RAG between the 1st of March and the 31st of October 2016
* Study Procedures performed within 3 days after enrollment in the study
* Relative or helper available who usually visits the patient at home at least once a week
* Absence of alcoholic excipient in the concomitant medication
Exclusion Criteria:
* Age \< 60 years old
* Admitted in the Geriatrics Department of Mulhouse after more than 48hours after admission to the GHRMSA
* Presence of the following symptoms :
* Hepatobiliary deficiency related to a primary biliary cirrhosis
* Autoimmune or viral cirrhosis
* Hepatocellular carcinoma
* Congenital metabolic disorder in protein glycosylation
* Known genetics variance in Tf B or D transferrin
* Living in an elderly care institution
* Already enrolled in this study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Benefit of Carbohydrate Deficient Transferrin to detect chronic alcohol abuse in the elderly compared to usual clinical detection tools
Timeframe: Within 3 days after enrollment in the study
Trial details
NCT IDNCT02822911
SponsorGroupe Hospitalier de la Region de Mulhouse et Sud Alsace